Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

Recruiting now · Phase 2

Conditions studied: Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP

In brief

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

Key facts

Study ID

NCT06189820

Run by

Erasme University Hospital

People needed

70

Starts

2023-03-09

Expected to finish

2027-03-09

Last updated by the study team

2024-01-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines

You may not qualify if…

• Pregnant or nursing patients
• Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
• Patients with an active lung neoplasm or any active neoplasm for blood samples

Where it is running

• Medecine — Brussels, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.